Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Cytokinetics stock

Learn how to easily invest in Cytokinetics stock.

Cytokinetics Inc is a biotechnology business based in the US. Cytokinetics shares (CYTK) are listed on the NASDAQ and all prices are listed in US Dollars. Cytokinetics employs 253 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Cytokinetics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CYTK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Cytokinetics stock price (NASDAQ: CYTK)

Use our graph to track the performance of CYTK stocks over time.

Cytokinetics shares at a glance

Information last updated 2022-06-25.
Latest market close$47.25
52-week range$17.72 - $48.10
50-day moving average $39.68
200-day moving average $37.57
Wall St. target price$61.58
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-3.21

Buy Cytokinetics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
Financial advice powered by relationships, not commissions.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cytokinetics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cytokinetics price performance over time

Historical closes compared with the close of $47.25 from 2022-06-24

1 week (2022-06-17) 16.44%
1 month (2022-05-27) 12.85%
3 months (2022-03-25) 29.56%
6 months (2021-12-27) 3.05%
1 year (2021-06-25) 110.00%
2 years (2020-06-26) 98.78%
3 years (2019-06-27) 326.83%
5 years (2017-06-27) 253.93%

Cytokinetics financials

Revenue TTM $65 million
Gross profit TTM $-89,510,000
Return on assets TTM -19.5%
Return on equity TTM -279.9%
Profit margin 0%
Book value $1.36
Market capitalisation $4 billion

TTM: trailing 12 months

Cytokinetics share dividends

We're not expecting Cytokinetics to pay a dividend over the next 12 months.

Have Cytokinetics's shares ever split?

Cytokinetics's shares were split on a 1:6 basis on 24 June 2013. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytokinetics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cytokinetics shares which in turn could have impacted Cytokinetics's share price.

Cytokinetics share price volatility

Over the last 12 months, Cytokinetics's shares have ranged in value from as little as $17.72 up to $48.1. A popular way to gauge a stock's volatility is its "beta".

CYTK.US volatility(beta: 1.22)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytokinetics's is 1.2246. This would suggest that Cytokinetics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Cytokinetics overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California. .

Frequently asked questions

What percentage of Cytokinetics is owned by insiders or institutions?
Currently 4.871% of Cytokinetics shares are held by insiders and 114.16% by institutions.
How many people work for Cytokinetics?
Latest data suggests 253 work at Cytokinetics.
When does the fiscal year end for Cytokinetics?
Cytokinetics's fiscal year ends in December.
Where is Cytokinetics based?
Cytokinetics's address is: 350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
What is Cytokinetics's ISIN number?
Cytokinetics's international securities identification number is: US23282W6057
What is Cytokinetics's CUSIP number?
Cytokinetics's Committee on Uniform Securities Identification Procedures number is: 23282W100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site